![First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors - eClinicalMedicine First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors - eClinicalMedicine](https://www.thelancet.com/cms/asset/2e367137-80c0-40c6-9ddd-bcd689ba8a67/gr1.jpg)
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors - eClinicalMedicine
![Study design. a Framework for the dose-escalation and dose-expansion... | Download Scientific Diagram Study design. a Framework for the dose-escalation and dose-expansion... | Download Scientific Diagram](https://www.researchgate.net/publication/350835604/figure/fig1/AS:1012002675761152@1618291648006/Study-design-a-Framework-for-the-dose-escalation-and-dose-expansion-study-of.png)
Study design. a Framework for the dose-escalation and dose-expansion... | Download Scientific Diagram
![Moving Beyond 3+3: The Future of Clinical Trial Design | American Society of Clinical Oncology Educational Book Moving Beyond 3+3: The Future of Clinical Trial Design | American Society of Clinical Oncology Educational Book](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/edbk/2021/edbk.2021.41/edbk_319783/20210531/images/large/edbk_319783-table1.jpeg)
Moving Beyond 3+3: The Future of Clinical Trial Design | American Society of Clinical Oncology Educational Book
![Alex A. Adjei, MD, PhD Designing Phase I Trials with Targeted Agents: Challenging Tradition. - ppt download Alex A. Adjei, MD, PhD Designing Phase I Trials with Targeted Agents: Challenging Tradition. - ppt download](https://images.slideplayer.com/29/9489814/slides/slide_37.jpg)
Alex A. Adjei, MD, PhD Designing Phase I Trials with Targeted Agents: Challenging Tradition. - ppt download
![Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma - ScienceDirect Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S095980492100040X-gr1.jpg)
Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma - ScienceDirect
![Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results | Nature Medicine Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results | Nature Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-023-02297-5/MediaObjects/41591_2023_2297_Fig1_HTML.png)
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results | Nature Medicine
![Translational phase I study with biomarker-defined end points. Phase I... | Download Scientific Diagram Translational phase I study with biomarker-defined end points. Phase I... | Download Scientific Diagram](https://www.researchgate.net/publication/264640460/figure/fig1/AS:282055268159519@1444258624826/Translational-phase-I-study-with-biomarker-defined-end-points-Phase-I-oncology-studies.png)
Translational phase I study with biomarker-defined end points. Phase I... | Download Scientific Diagram
![Inter-patient and intra-patient dose escalation strategy. Patients were... | Download Scientific Diagram Inter-patient and intra-patient dose escalation strategy. Patients were... | Download Scientific Diagram](https://www.researchgate.net/publication/46403694/figure/fig2/AS:667189245931545@1536081720859/Inter-patient-and-intra-patient-dose-escalation-strategy-Patients-were-sequentially.png)
Inter-patient and intra-patient dose escalation strategy. Patients were... | Download Scientific Diagram
![Statistical controversies in clinical research: building the bridge to phase II—efficacy estimation in dose-expansion cohorts - ScienceDirect Statistical controversies in clinical research: building the bridge to phase II—efficacy estimation in dose-expansion cohorts - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419322458-gr1.jpg)
Statistical controversies in clinical research: building the bridge to phase II—efficacy estimation in dose-expansion cohorts - ScienceDirect
![Bertrand Delsuc on X: "@BiotechRadar CUARt123 AML: RP2D definition, extensive DLT recording (differences vs ALL), dose expansion, risks assessment https://t.co/aDIcKjyNon" / X Bertrand Delsuc on X: "@BiotechRadar CUARt123 AML: RP2D definition, extensive DLT recording (differences vs ALL), dose expansion, risks assessment https://t.co/aDIcKjyNon" / X](https://pbs.twimg.com/media/CzqZ9KGXUAAXpDN.jpg)
Bertrand Delsuc on X: "@BiotechRadar CUARt123 AML: RP2D definition, extensive DLT recording (differences vs ALL), dose expansion, risks assessment https://t.co/aDIcKjyNon" / X
![emDOCs.net – Emergency Medicine EducationPush-Dose Vasopressors: An Update for 2019 - emDOCs.net - Emergency Medicine Education emDOCs.net – Emergency Medicine EducationPush-Dose Vasopressors: An Update for 2019 - emDOCs.net - Emergency Medicine Education](https://i0.wp.com/www.emdocs.net/wp-content/uploads/2019/04/Screen-Shot-2019-04-21-at-5.23.21-PM.png?fit=1576%2C1064&ssl=1)
emDOCs.net – Emergency Medicine EducationPush-Dose Vasopressors: An Update for 2019 - emDOCs.net - Emergency Medicine Education
![Statistical controversies in clinical research: building the bridge to phase II—efficacy estimation in dose-expansion cohorts - ScienceDirect Statistical controversies in clinical research: building the bridge to phase II—efficacy estimation in dose-expansion cohorts - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419322458-gr2.jpg)
Statistical controversies in clinical research: building the bridge to phase II—efficacy estimation in dose-expansion cohorts - ScienceDirect
![Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician | JCO Precision Oncology Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician | JCO Precision Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/po/2021/po.2021.5/po.20.00379/20210128/images/large/po.20.00379t2.jpeg)